China has international patents for new anti-AIDS drug research and development into the fast lane

an international cooperation agreement on the development of new drugs to fight AIDS based on international patents of Chinese scientists and their preclinical research results signed in Shanghai on the 15th, Shanghai Target Drug LimitedDivisionand the department ofAvex
a, Australia,will jointly promote the follow-up research and development of the new aids candidate "nifveiro"(
Nifeviroc), which marks the invasion of China's inhibitor-based AIDS treatment drugs research and developmentSince February000, the Chinese Academy of Sciences, Shanghai Institute of Life Sciences, biochemical cell research, Yan Gang academician and the Chinese Academy of Sciences Shanghai Institute of Organic Chemistry, Ma Dawei researcher, jointly carried out the HIV invasion of human cell link of drug design and screening, lasted 3 years, finally found a number of promising anti-HIV infection candidate drug molecules, and applied for an international patentIn order to speed up the follow-up research and development of candidate drug molecules,2
June 003, the Shanghai Institute of Life Sciences of the Chinese Academy of Sciences and the Shanghai Institute of Organic Chemistry of the Chinese Academy of Sciences jointly initiated the establishment of the Shanghai Target Drug LimitedDivisionwith knowledge capital, and theof Shanghai Fudan Zhangjiang Biopharmaceutical LimitedDivision With the support of the Ministry of Science and Technology , the Shanghai Science and Technology Commission and other , less than 3 years , the will be the Shanghai Science and Technology Commission's major special "Nifivero" pre-clinical research work successfully completed 2
february , the State Food, Drug
administration approved "Nifiviro" into the clinical research , human trials are about to begin At present, , the international patent "Nifivero" has entered 14 countries and regions, including the United States , Japan , the European Union It is reported that pre-clinical trials show that the effect of "nifiveviro" in vitro anti-HIV infection is comparable with similar international candidatedrugs The signing of this international cooperation agreement has put the follow-up research and development of "Nifivero" on the fast track of international industrial, academic and research cooperation Dr Chen Li
, general manager of Shanghai Target Drug Limited , said the terms of the agreement were formulated in accordance with the international rules for the development of new drugs, with the aim of using the international drug research and development platform with specialized and a high starting point , speeding up drug research and development, and opening the international market channel for the development of subsequent new drugs It is reported that "Nifivero" follow-up full research and development time will be four or five years (
Xinhua News Agency, without permission, it is strictly prohibited to reproduce)